Cardiac Dimensions has received CE mark approval for its carillon mitral contour system, a novel therapy for treating heart failure patients suffering from functional mitral regurgitation (FMR).

The mitral contour system consists of a proprietary, implantable device with a percutaneous catheter delivery system.

The approval is backed by Amadeus and Titan clinical trials of the Carillon system, which demonstrated reduction in FMR and improvement in functional capacity and quality of life.

Another study, called Titan II, was recently initiated to further the clinical experience.

Commercial launch of the device in Europe will begin in 2012, the company said.


How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.